Holen Sie sich die Stockscreener-App
223.97
0.12%
-0.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$224.09
Offen:
$224.28
24-Stunden-Volumen:
260.65K
Relative Volume:
0.25
Marktkapitalisierung:
$32.60B
Einnahmen:
$5.40B
Nettoeinkommen (Verlust:
$1.49B
KGV:
22.14
EPS:
10.1168
Netto-Cashflow:
$1.78B
1W Leistung:
+1.73%
1M Leistung:
-11.48%
6M Leistung:
-20.45%
1J Leistung:
+9.09%
1-Tages-Spanne:
$223.59
$226.63
1-Wochen-Bereich:
$219.01
$226.63
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
223.75 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
451.71 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.99 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.52 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
43.77 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
4,837 Shares in ResMed Inc. $RMD Acquired by Runnymede Capital Advisors Inc. - MarketBeat
Wealth Enhancement Advisory Services LLC Has $1.66 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Element Squared LLC Buys Shares of 6,067 ResMed Inc. $RMD - MarketBeat
Aberdeen Group Reduces Stake in ResMed Inc. - National Today
Aberdeen Group plc Sells 37,737 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Brett Sandercock Sells Shares of ResMed Inc (RMD) - gurufocus.com
RESMED INC. R (RME.MU) Q1 FY2025 earnings call transcript - Yahoo Finance
Resmed CFO Sandercock sells $224k in stock By Investing.com - Investing.com South Africa
Resmed CFO Sandercock sells $224k in stock - investing.com
ResMed (RMD) CFO Sandercock sells 1,000 shares in open market trade - Stock Titan
J. Safra Sarasin Holding AG Sells 10,794 Shares of ResMed Inc. $RMD - MarketBeat
Spire Wealth Management Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - gurufocus.com
ResMed Inc. (RMD) stock price, news, quote and history - Yahoo Finance UK
ResMed Inc. (RMD.AX) stock price, news, quote and history - Yahoo Finance Singapore
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
ResMed Inc. (RMD) latest stock news and headlines - Yahoo Finance Singapore
Resmed director Farrell sells $450,000 in stock By Investing.com - Investing.com India
Resmed director Farrell sells $450,000 in stock - investing.com
Resmed Insider Sold Shares Worth $450,000, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
Peter C. Farrell (RMD) sells 6,000 shares via Rule 144 notices (NYSE: RMD) - Stock Titan
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026 - The Manila Times
Resmed to post quarterly results after market close on April 30 - Stock Titan
Affiliate proposes three 1,000-share sales for RMD (NYSE: RMD) — broker listed - Stock Titan
ResMed Inc. stock rises Tuesday, still underperforms market - marketwatch.com
Is It Time To Revisit ResMed (RMD) After Recent Share Price Weakness? - Yahoo Finance
ResMed (RMD) Valuation Check After Recent Share Price Weakness - Sahm
ResMed back on the Buy List - intelligentinvestor.com.au
ResMed Earnings Preview: What to Expect - Yahoo Finance
SG Americas Securities LLC Cuts Stock Position in ResMed Inc. $RMD - MarketBeat
Eagleford Energy and ResMed Compared - National Today
ResMed Inc. Stock: Navigating Sleep Apnea Market Leadership Amid Demographic Tailwinds and Digital I - AD HOC NEWS
ResMed Inc. (RMD) Launches Global Sleep Institute at World Sleep Congress - MSN
RBC Capital Maintains ResMed Inc.Depositary Receipt (RSMDF) Outperform Recommendation - msn.com
ResMed stock price forecast: technical weakness persists as RMD struggles below key moving averages - Traders Union
Vanguard (RMD) disaggregates holdings; reports zero ownership in ResMed - Stock Titan
Regatta Capital Group LLC Invests $2.51 Million in ResMed Inc. - nationaltoday.com
Regatta Capital Group LLC Takes $2.51 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed & Netwealth: A Fresh Look at Valuation Trends - Kalkine Media
Dakota Wealth Management Has $8.18 Million Holdings in ResMed Inc. $RMD - MarketBeat
Assenagon Asset Management S.A. Has $19.43 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock outperforms market despite losses on the day - MarketWatch
ResMed Inc. stock: Leader in sleep and respiratory care with strong North American market presence - AD HOC NEWS
Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks - Yahoo Finance
Is ResMed stock underperforming the Nasdaq? - MSN
ResMed Inc. (RMD.AX) Alternative Data AnalyticsSocial & Digital Signals - Meyka
ResMed Inc stock faces pressure amid slowing sleep apnea device demand and insurance reimbursement h - AD HOC NEWS
ResMed Share Price Insights: Is RMD Worth Watching in 2026? - Kalkine Media
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):